GB202213849D0 - Crystalline forms of bexagliflozin, processes for the preparation and use thereof - Google Patents
Crystalline forms of bexagliflozin, processes for the preparation and use thereofInfo
- Publication number
- GB202213849D0 GB202213849D0 GBGB2213849.9A GB202213849A GB202213849D0 GB 202213849 D0 GB202213849 D0 GB 202213849D0 GB 202213849 A GB202213849 A GB 202213849A GB 202213849 D0 GB202213849 D0 GB 202213849D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- bexagliflozin
- processes
- preparation
- crystalline forms
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- BTCRKOKVYTVOLU-SJSRKZJXSA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(OCCOC3CC3)=CC=2)=C1 BTCRKOKVYTVOLU-SJSRKZJXSA-N 0.000 title 1
- 229950003611 bexagliflozin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2213849.9A GB202213849D0 (en) | 2022-09-22 | 2022-09-22 | Crystalline forms of bexagliflozin, processes for the preparation and use thereof |
| PCT/IB2023/059365 WO2024062421A1 (fr) | 2022-09-22 | 2023-09-21 | Bexagliflozine sous forme de monohydrate, de dihydrate ou amorphe |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2213849.9A GB202213849D0 (en) | 2022-09-22 | 2022-09-22 | Crystalline forms of bexagliflozin, processes for the preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202213849D0 true GB202213849D0 (en) | 2022-11-09 |
Family
ID=83978687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2213849.9A Ceased GB202213849D0 (en) | 2022-09-22 | 2022-09-22 | Crystalline forms of bexagliflozin, processes for the preparation and use thereof |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202213849D0 (fr) |
| WO (1) | WO2024062421A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011153712A1 (fr) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène |
| CN108239055B (zh) | 2016-12-23 | 2023-07-18 | 杭州领业医药科技有限公司 | 一种thr1442 l-天冬氨酸共晶、其制备方法及药物组合物 |
| EP3621977A4 (fr) * | 2017-05-09 | 2021-04-07 | Piramal Pharma Limited | Procédé de préparation d'inhibiteur de sglt2 et de ses intermédiaires |
| WO2021243645A1 (fr) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Activateur de glucokinase pour le traitement d'un diabète avec insuffisance rénale |
-
2022
- 2022-09-22 GB GBGB2213849.9A patent/GB202213849D0/en not_active Ceased
-
2023
- 2023-09-21 WO PCT/IB2023/059365 patent/WO2024062421A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024062421A1 (fr) | 2024-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202101909D0 (en) | Novel crystalline form of pyroxa-sulfone, methods for its preparation and use of the same | |
| EP3934652A4 (fr) | Composés, compositions et procédés pour le traitement d'une maladie | |
| SG11202109780VA (en) | Process for the preparation of battery precursors | |
| SI3594199T1 (sl) | Kristalinični 2-fluoro-3-nitrotoluen in postopek za njegovo pripravo | |
| EP3883562A4 (fr) | Formes purifiées de rofécoxib et procédés de fabrication et d'utilisation | |
| IL289453A (en) | A process for the preparation of ridinilazole and crystalline forms thereof | |
| IL290185A (en) | Crystalline forms of risdiplam and their preparation process | |
| EP3986870A4 (fr) | Nouvelle forme cristalline d'olaparib et procédé de préparation associé | |
| SG11202108863WA (en) | Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof | |
| EP4073049A4 (fr) | Nouvelles formes cristallines de flufénacet, leurs procédés de préparation et leur utilisation | |
| ZA202200964B (en) | Salts of a compound, crystal forms of the salts and preparation method and use thereof | |
| GB202002560D0 (en) | Crystalline forms of voxelotor, and processes for the preparation thereof | |
| EP3810321A4 (fr) | Métallophosphates cristallins, leur procédé de préparation et leur utilisation | |
| GB202213849D0 (en) | Crystalline forms of bexagliflozin, processes for the preparation and use thereof | |
| EP4073050A4 (fr) | Nouvelles formes cristallines de flufénacet, son procédé de préparation et son utilisation | |
| WO2018165269A3 (fr) | Formes cristallines de l'acide obéticholique | |
| IL290540A (en) | Compounds suitable for the treatment and prevention of muscle wasting and other conditions | |
| ZA202107810B (en) | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof | |
| EP4027999A4 (fr) | Forme cristalline d'un inhibiteur de la tyrosine kinase multiple, son procédé de préparation et son utilisation | |
| EP3877379A4 (fr) | Forme cristalline de chlorhydrate de nilotinib, son procédé de préparation et composition pharmaceutique le contenant | |
| EP3810324A4 (fr) | Métallophosphates cristallins, leur procédé de préparation et leur utilisation | |
| EP3810551A4 (fr) | Métallophosphates cristallins, leur méthode de préparation et leur utilisation | |
| EP3793546A4 (fr) | Formes cristallines d'inhibiteur d'ebna1 et procédés de préparation et méthodes d'utilisation de celles-ci | |
| EP3708568A4 (fr) | Composé capable d'inhiber la phosphodiestérase 4, son procédé de préparation et son utilisation médicale | |
| WO2020049598A3 (fr) | Polymorphes d'apalutamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |